Target intelligence / Profile preview

Helper T cell activation (activation of CD4+ T cells) (None)

Target
None
Molecular classification
Other (cellular process, not a molecule)
01

Overview

Activation of helper T cells refers to the process by which CD4+ T lymphocytes recognize antigen-bound MHC class II on antigen-presenting cells, receive co-stimulatory signals (primarily through CD28 and other receptors), and undergo clonal expansion and differentiation into various effector subtypes (Th1, Th2, Th17, etc.). This activation orchestrates adaptive immune responses, driving antibody production (by B-cell help), cell-mediated immunity, cytokine secretion, and immune memory formation. Therapeutic targeting of this process typically involves inhibition or modulation of molecular participants like the T cell receptor (TCR), CD3, CD28, CD40L, or related cytokine and signal transduction pathways. Overactivation or misregulation can lead to allergy, autoimmunity, and inflammatory disease, while deficient activation can result in immunodeficiency and poor infection or tumor control.

Other names
Activation of helper T cellsCD4+ T cell activationTh cell activationT lymphocyte activation
02

Mechanism of action

Inhibition of co-stimulatory signals (blocking CD28/B7 interaction); Inhibition of T-cell receptor signaling; Blocking cytokine signaling (e.g. IL-2, IL-4, IFN-γ); Inhibition of CD40L/CD40 interaction; Suppression of transcription factors (e.g. NFAT, STATs)

03

Biological functions

Immune responseSignal transductionCell proliferationDifferentiationCytokine secretionAntibody class switching
04

Disease associations

Inflammation (autoimmune disease, allergy, asthma, Type IV hypersensitivity, etc.)Infection (protective immune response to bacteria, viruses, fungi, parasites)Cancer (immune surveillance, antitumor response)Immunodeficiency (e.g. HIV, SCID, affects T cell activation)
05

Safety considerations

Immunosuppression (increased risk of infection and cancer)Cytokine release syndrome ("cytokine storm")Autoimmunity (overactivation of T-helper cells)Allergic responses (Th2 overactivation)Loss of tolerance (can drive autoimmunity or transplant rejection)
06

Interacting drugs

Muromonab-CD3 (OKT3)

9 more in the full profile.

07

Biomarkers

CD4 expression levelsCD25 (IL-2 receptor alpha chain) upregulationIL-2 secretionIFN-γ, IL-4, IL-17 production (Th1, Th2, Th17 profiles)CD40L surface expressionActivation-induced cell surface markers (e.g. CD69, CD25)

Beyond the preview

Go deeper on Helper T cell activation (activation of CD4+ T cells) (None).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Helper T cell activation (activation of CD4+ T cells) (None).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call